印度代购提示您，本品他替瑞林（Taltirelin），促甲状腺激素释放激素（TRH）类似物，在日本已经获准作为治疗脊髓小脑变性疾病（SCD）药物进入临床，用于改善共济失调步态。 作为一种对症治疗药物，他替瑞林不是针对病因的治疗，不是针对异常蛋白的药物，而是针对症状的治疗方法，对于神经退行性疾病患者（包括遗传性共济失调）如果有效，需要长期服用，停药就失去作用。共济失调患者群体的病种非常复杂多样，每个患者的疾病不同，临床表现不同，病程不同，一种药物不可能改善所有患者的症状，病友需要理性面对这个药物。

Taltirelin, a thyroid stimulating hormone releasing hormone (TRH) analogue, has been approved in Japan as a treatment for spinocerebellar degeneration disease (SCD) to improve ataxic gait. As a symptomatic treatment, tatirelin is not a treatment for the cause or abnormal protein, but a treatment for the symptoms. If it is effective for patients with neurodegenerative diseases (including hereditary ataxia), it needs to be taken for a long time, and the effect will be lost when the drug is stopped. The diseases of patients with ataxia are very complex and diverse. Each patient has a different disease, different clinical manifestations and different course of disease. It is impossible for one drug to improve the symptoms of all patients.

他替瑞林

　　小脑性共济失调是一个症状，诊断非常复杂和困难。背后有相当多的病因，至少包括遗传性、获得性、变性性三大类原因，每种里面的疾病又不胜枚举。多系统萎缩是变性性小脑性共济失调的代表疾病，这些病因多数不好确认，需要通过血液、脑脊液、影像等方法加以证实或排除，有时只有通过去世后的尸检才能证实最终的诊断。

　　印度代购提示您，本品在做临床试验时，通常需要选择符合某一诊断标准的一种疾病，这就使研究人群相对单一，研究结果也不太容易推广至其它类型。因此在看待研究结果时，需要注意所研究的样本人群，科学理性地对待。而有些人可能有意无意地模糊这个概念，让患者误以为对所有情况都适用。

When clinical trials are conducted, it is often necessary to select a disease that meets a certain diagnostic criteria, making the study population relatively homogeneous and the results difficult to generalize to other types. Therefore, when viewing the research results, we should pay attention to the sample population studied and treat them scientifically and rationally. And some people may intentionally or unknowingly blur the concept into thinking that it applies to all situations.